Pre-made Bintrafusp benchmark antibody ( Whole mAb Fusion, anti-CD274/PD-L1 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-071

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-071 Category Tag

Product Details

Pre-Made Bintrafusp biosimilar, Whole mAb Fusion, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Bintrafusp biosimilar, Whole mAb Fusion, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody

INN Name

Bintrafusp

Target

CD274

Format

Whole mAb Fusion

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Lambda

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

Active

100% SI Structure

4nki:HL/5grj:HL

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2015

Companies

AIO Studien gGmbH,Array BioPharma,Chong Kun Dang,Dana-Farber Cancer Institute,Debiopharm,eFFECTOR Therapeutics,EMD Serono,Forty Seven,Fred Hutchinson Cancer Research Center,Gachon University Gil Medi

Conditions Approved

Merkel cell carcinoma,Urogenital cancer

Conditions Active

Renal cell carcinoma,Breast cancer,Diffuse large B cell lymphoma,Gastric cancer,Head and neck cancer,Non-small cell lung cancer,Ovarian cancer,Bladder cancer,Endometrial cancer,Fallopian tube cancer,

Conditions Discontinued

NA

Development Tech

Human Phage Display

Previous Name

NA

Gm Offical Target Name

CD274/PD-L1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide